Mounjaro®
Starting from £179.99/mo
Start journey Learn moreAt the three-month mark, most people using Mounjaro for weight management have completed two to three dose increases and are somewhere between 5mg and 10mg. Clinical trial data show average weight loss of roughly 8–12% of starting body weight by this point, depending on the dose reached and how well the body has tolerated titration. That range comes from the SURMOUNT-1 trial, published in the New England Journal of Medicine, in which participants on higher maintenance doses ultimately lost around 20–21% of body weight over 72 weeks — meaning the 12-week window is still well within the early phase of change. Mounjaro (tirzepatide) is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is clinically suitable before any treatment is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Twelve weeks into Mounjaro treatment, two people who started the same day can show very different numbers on the scale. That is not a flaw in the medicine; it reflects where each person sits in the titration schedule. Mounjaro begins at 2.5mg, a dose whose job is to let the body acclimatise, not to drive significant weight loss. The first real appetite suppression for most people arrives at 5mg, and it often strengthens again at 7.5mg. Someone who has reached 7.5mg or 10mg by week 12 is likely to show stronger results than someone who needed an extra four weeks at 5mg to manage nausea.
Body composition also matters. People with a higher starting BMI tend to see larger absolute losses in kilograms early on, though percentage-of-body-weight comparisons are more meaningful when gauging how the medicine is working for you. If you want a realistic picture of the typical trajectory across the whole first year, average Mounjaro weight loss figures broken down by time point give a useful reference.
One quick habit worth building: note your weight on the same day each week, first thing in the morning, before eating. A rolling four-week average smooths out the fluctuations that come from water retention, digestion and normal variation. A single weigh-in can mislead; four in a row tell a story.
SURMOUNT-1 followed thousands of adults with obesity over 72 weeks. At around the 12-week mark in that dataset, participants on the higher doses had lost roughly 8–10% of body weight on average. By week 24, that figure had climbed to around 15%, and it continued rising through to the end of the trial. The 72-week endpoint of approximately 20–21% at 15mg is the headline, but it was built slowly, with most of the loss occurring after the three-month window.
What the trial data cannot do is predict your result. Individual variation is real: genetics, baseline metabolic rate, how closely someone follows dietary guidance, activity levels and whether any conditions such as type 2 diabetes are also present all shift the outcome. The NICE appraisal of tirzepatide (TA1026) notes that continuing treatment is reviewed if less than 5% weight loss has occurred after six months at the highest tolerated dose, so even at three months, falling short of a specific number is not a signal to stop. Six months at the right dose is the relevant clinical benchmark. For context on how this window fits into the longer arc, the picture at month four is worth reading alongside this one.
At each repeat order, a prescriber reviews your progress, not as a formality, but because the clinical picture at three months shapes what happens next. The questions being considered are: Has the current dose been tolerated? Is there enough evidence of response to justify continuing? Would a dose increase be appropriate, or is there a clinical reason to hold?
This is the stage where many people find that initial nausea has settled, appetite is noticeably reduced and the weight trend is clear. Some find the losses have come quickly; others are still finding their footing with the medicine. If you started Mounjaro after two months of early treatment and are now assessing what three months has delivered, the right frame is progress relative to your starting point, not a comparison with someone else's six-month total.
If you are weighing up whether to continue, switch dose, or simply want to understand your results in context, that conversation belongs with your prescriber. At nume, every repeat goes through a same-day clinical review by a GPhC-registered prescriber, a real clinician reads your update, not a queue system. You can explore how the overall treatment process works on the Mounjaro overview page, and if cost is a factor in your thinking, our Mounjaro price comparison page covers what to expect from private treatment pricing in the UK.
If you are still in the early weeks and wondering when the medicine starts to act, how long Mounjaro takes to work covers the mechanism and timeline in detail. Ready to begin or to discuss your current results with a prescriber? Start your free consultation and a clinician will review your case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.